StreetAlpha.app
Home › Stocks › CLLS

Cellectis S.A. (CLLS)

$0.92
▼ −6.39%
LAST CLOSE · NOV 20

Cellectis develops cell therapies for cancer and genetic diseases using gene editing, and licenses its technology to drug developers. It last closed at $0.92 on Nov 20, down 6.39% on the day.

AI Auto Pilots
Is CLLS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold CLLS.

Key Stats

Fiscal 2025
Results
Revenue
$72.9M
+75.8% vs a year ago
Net income
−$67.6M
−92.7% margin
Free cash flow
−$41.8M
−57.2% margin
Operating margin
−45.3%
−$33.1M operating income
Balance sheet
Cash & equivalents
$61.5M
At Dec 31
Shareholder equity
$75.9M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $30.3M$30.3MFY2021FY2022: $19.2M$19.2MFY2022FY2023: $755K$755KFY2023FY2024: $41.5M$41.5MFY2024FY2025: $72.9M$72.9MFY2025

From CLLS's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Mar 20). Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on the calendar yet
Consensus EPS forecast
EPS and revenue estimates
Year-ago EPS
Same quarter last year
Options-implied move
Move priced in by options
Analyst consensus
Ratings from the last 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on CLLS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on CLLS

Technical Analysis

CLLS · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 20% below its 20 day and 34% below its 50 day average. It is 210% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 38), near oversold. The nearest support is the 52 week low at $0.88, and the nearest resistance the Pivot at $0.94.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNear oversold
VolatilityHigh, 14.7%/day
Key levels
$5.4552 week high+492.4%
$2.85200 day average+209.8%
$2.13100 day average+131.5%
$1.25Swing high (Nov 4)+35.9%
$1.2350 day average+33.7%
$1.1020 day average+19.6%
$0.98Pivot R1+6.5%
$0.94Pivot+2.2%
$0.92Last close
$0.8852 week low−4.3%
$0.88Pivot S1−4.3%
$0.88Swing low (Oct 19)−4.3%
Indicators
RSI (14)37.74Weak, oversold below 30Neutral
MACD-0.08Below its signal lineBearish
Stochastic4.8Near the bottom of its rangeOversold
ADX (14)26.3Trending down
Williams %R-97.1Oversold below −80, overbought above −20Oversold
CCI (20)-134.4Oversold below −100, overbought above 100Oversold
Rate of change−13.9%Change over 10 sessionsBearish
ATR (14)$0.13Typical daily range, 14.7% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CLLS

What happened before

See how CLLS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow CLLS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How CLLS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for CLLSHow many large options trades hit CLLS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

CLLS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲12 buying vs 9 selling
  • ●Shares held by funds +0.3%
  • ▲Funds holding +4
  • ●No superinvestor moves
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding3127+14.8%
In funds' top 1001−100.0%
Held by funds–––
New / increased8 / 43 / 1+200.0%
Reduced / sold out4 / 58 / 8−43.8%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CLLS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CLLS is in one of them and how their past CLLS trades turned out.

CLLS in the AI portfolios
Loading…

CLLS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CLLS in an article yet. Here's the latest on the wider market.

CLLS in the news

About Cellectis S.A.

Cellectis is a biotechnology company based in Paris, France, that develops cell and gene therapies using gene editing. Its main focus is cancer treatments made from CAR T cells taken from healthy donors, which can be produced in batches and shipped as ready to use products rather than made for each patient. The company also develops gene therapies for genetic diseases and licenses its technology to drug developers such as AstraZeneca, Allogene, Servier and Iovance.

Headquarters
Paris, Lle-De-France
Founded
1999